Healthcare Industry News: Baxter International
News Release - October 11, 2007
Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.MALVERN, Pa., Oct. 11 (HSMN NewsFeed) -- Solstice Neurosciences, Inc. ("Solstice") announced the appointment of Dennis L. Smith to its Board of Directors. Mr. Smith will serve as Executive Chairman replacing James Thomas, who remains on the Board having served as Chairman since Solstice was founded in July 2004.
Mr. Smith brings unique specialty pharmaceutical industry experience and expertise to Solstice that will be invaluable in providing guidance and leadership for growth and maximizing stockholder value. Mr. Smith will work with the Board and Solstice management to review current operations and develop strategic options.
Mr. Smith has worked in the pharmaceutical industry since 1973, and most recently served as President and Chief Executive Officer of INO Therapeutics LLC., a specialty pharmaceutical company with strengths in development, marketing, and sales of critical care drugs and drug/device combinations, and focused on making innovative therapies available to healthcare professionals and patients. Prior to INO, Mr. Smith spent 15 years with DuPont Pharmaceutical Company, where he served as President of U.S. Operations, Executive Vice President of Global Health Systems, Executive Vice President in Europe, and Vice President and General Manager in Canada, among numerous other positions at DuPont Pharmaceuticals and DuPont Merck. Mr. Smith was also employed at Baxter International and Sandoz Pharmaceuticals (now Novartis). Mr. Smith is a graduate of Michigan State University and the Lake Forest Graduate School of Business.
"We are extremely pleased to have Dennis join the Board of Directors of Solstice," said Shawn Patrick O'Brien, President and Chief Executive Officer. "His wide-ranging experience in the biopharmaceutical industry will undoubtedly prove to be extremely valuable as Solstice continues to evolve and broaden our product portfolio globally," Mr. O'Brien said.
"I am excited to be joining the Board and eager to work with Shawn and the Solstice team as well as the Board members to better understand this dynamic and growing business and help lead the future direction. I also look forward to interacting with employees and the customers who treat the patients we ultimately serve," said Mr. Smith.
About Solstice Neurosciences, Inc.
Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, MYOBLOC® (Botulinum Toxin Type B) Injectable Solution, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold in the EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit www.solsticeneuro.com.
Myobloc® and NeuroBloc® are registered trademarks of Solstice Neurosciences, Inc.
Source: Solstice Neurosciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.